The journal retracts the 28th August 2020 article cited above.
Following publication, concerns were raised regarding the integrity of Figures 1 and 3. An investigation was conducted in accordance with Frontiers guidelines and the authors failed to provide a satisfactory explanation.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Editor-in-Chief of Frontiers. The authors agree to this retraction.
Summary
Keywords
endometrial cancer, CCT7, Myometrial invasion, FIGO stage, overall survival
Citation
Frontiers Editorial Office (2021) Retraction: Clinical Significance, Cellular Function and Potential Molecular Pathways of CCT7 in Endometrial Cancer. Front. Oncol. 10:641611. doi: 10.3389/fonc.2020.641611
Received
14 December 2020
Accepted
15 December 2020
Published
14 January 2021
Approved by
Giuseppe Giaccone, Cornell University, United States
Volume
10 - 2020
Updates
Copyright
© 2021 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org
This article was submitted to Women’s Cancer, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.